FP
FatherhoodClinician • MB
Maternal Medicine • Canadian Clinical Reference

Maternal Health & Clinical Complications

Pathophysiology, SOGC clinical guidelines, diagnostic workup, and pharmacotherapy paired with empathetic partner guidance and warning sign surveillance.

FIRST TRIMESTER•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 343

Nausea & Vomiting of Pregnancy (NVP) and Hyperemesis Gravidarum

Clinical Executive Summary
  • •NVP affects 70-80% of pregnant individuals; onset typically at 4-6 weeks, peaking at 8-12 weeks, resolving by 16-20 weeks.
  • •PUQE (Pregnancy-Unique Quantification of Emesis) score objectively stratifies mild (<=6), moderate (7-12), and severe (13-15) disease.
  • •First-line pharmacotherapy in Canada: Doxylamine succinate 10mg / Pyridoxine HCl 10mg (Diclectin) up to 4 tabs daily.
  • •Hospitalize if persistent ketonuria, electrolyte derangement (hypokalemia, hypochloremic metabolic alkalosis), weight loss > 5% pre-pregnancy weight, or inability to tolerate oral fluids.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 426

Preeclampsia & Hypertensive Disorders of Pregnancy

Clinical Executive Summary
  • •Hypertensive disorders affect 5-10% of pregnancies globally and represent a leading cause of maternal and perinatal morbidity.
  • •Diagnostic criteria (SOGC): Gestational hypertension (BP >= 140/90 mmHg on two occasions >= 4 hours apart after 20 weeks) PLUS either proteinuria (>= 0.3 g/24h or urine protein:creatinine ratio >= 30 mg/mmol) OR new-onset adverse condition / end-organ dysfunction (thrombocytopenia, transaminitis, renal insufficiency, pulmonary edema, neurological/visual symptoms).
  • •Prophylaxis: Low-dose ASA (162 mg at bedtime) initiated before 16 weeks gestation in high-risk patients reduces preterm preeclampsia by >60%.
  • •Emergency treatment for severe hypertension (BP >= 160/110 mmHg): Labetalol 20mg IV over 2 min, hydralazine 5-10mg IV, or nifedipine 10mg PO. Seizure prophylaxis: Magnesium Sulfate (4g IV loading dose, then 1g/hr infusion).

Pathophysiology: Defective Placentation & Endothelial Activation

The primary root cause of preeclampsia is failed trophoblastic remodeling of maternal uterine spiral arteries during early second trimester. Normally, low-resistance, high-capacitance vessels are created. In preeclampsia, spiral arteries remain narrow and muscular, leading to intermittent placental ischemia-reperfusion injury and placental oxidative stress. The ischemic placenta releases anti-angiogenic factors into maternal circulation, primarily soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng). These bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), causing widespread maternal systemic endothelial dysfunction, microvascular vasospasm, capillary leakage, and microthrombosis.

HELLP Syndrome & Severe Complications

HELLP syndrome represents a severe variant characterized by:

  • •Hemolysis (microangiopathic hemolytic anemia): abnormal blood smear with schistocytes, elevated LDH (>600 U/L), low haptoglobin, elevated unconjugated bilirubin.
  • •Elevated Liver enzymes: AST or ALT >= 2x upper limit of normal.
  • •Low Platelets: thrombocytopenia (< 100 x 10^9/L).
  • •Eclampsia: new-onset generalized tonic-clonic seizures in a preeclamptic patient. Management requires urgent airway support and IV Magnesium Sulfate.

Inpatient Management & Delivery Timing (SOGC)

Delivery is the only definitive cure for preeclampsia, but timing balances maternal stability against fetal prematurity:

  • •>= 37 weeks gestation: Delivery indicated promptly upon diagnosis.
  • •34 to 36+6 weeks: Delivery indicated if severe hypertension, non-reassuring fetal status, or progressive lab derangements.
  • •< 34 weeks: Expectant management in a tertiary care center (e.g. Women's Hospital HSC Winnipeg) with maternal-fetal medicine consultation, antenatal corticosteroids (Betamethasone 12mg IM q24h x 2 doses) for fetal lung maturation, and continuous maternal-fetal surveillance, provided maternal status remains stable without severe organ failure.
Authoritative Clinical References:

• SOGC Clinical Practice Guideline No. 426: Hypertensive Disorders of Pregnancy (Society of Obstetricians and Gynaecologists of Canada, 2022)

• Rolnik DL, et al. ASPRE trial: Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377:613-622. (NEJM, 2017)

Last reviewed: 2026-09
LABOUR•Grade A (High/RCTs)•SOGC Intrapartum Clinical Care Guidelines

Labour Stages, Physiology & The Father's Tactical Support Guide

Clinical Executive Summary
  • •Stage 1 Latent Phase: Cervical dilation 0 to 5 cm; gradual effacement. Can last 12-24+ hours in nulliparous women; best managed in comfortable home environment.
  • •Stage 1 Active Phase: Cervical dilation 6 to 10 cm; cervical dilation rate typically >= 0.5–1.0 cm/hr. Hospital admission threshold.
  • •Stage 2: Full cervical dilation (10 cm) to delivery of the infant. Pushing phase; passive descent vs active pushing.
  • •Stage 3: Delivery of the infant to complete expulsion of placenta. Active management of third stage of labour (AMTSL) with Oxytocin 10 IU IM/IV prevents postpartum hemorrhage (PPH).
  • •Continuous labour support by partner/doula significantly decreases Cesarean section rates by 25-39%, reduces analgesia requirements, and improves 5-minute Apgar scores (Cochrane 2017).
INFANT SAFETY•Grade A (High/RCTs)•CPS Joint Statement on Safe Sleep for Babies

Newborn Safe Sleep Architecture: SIDS Prevention & CPS Guidance

Clinical Executive Summary
  • •Sudden Infant Death Syndrome (SIDS) remains the leading cause of post-neonatal infant mortality in Canada.
  • •Triple Risk Model: 1) Vulnerable infant (underlying brainstem autonomic/cardiorespiratory arousal defect); 2) Critical developmental period (peak 2-4 months); 3) Exogenous environmental stressor (prone sleeping, soft bedding, smoke exposure, overheating).
  • •Room-sharing without bed-sharing for the first 6 months decreases SIDS risk by up to 50%.
  • •ABCs of Safe Sleep: Alone, on their Back, in a bare Crib with a firm, flat mattress complying with Canadian Cribs, Cradles and Bassinets Regulations.
DELIVERY•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 381 (Operative Vaginal Birth)

Operative Vaginal Delivery: Vacuum Extraction vs. Forceps

Clinical Executive Summary
  • •Indicated for prolonged second stage (nulliparous >3h with epidural / >2h without; multiparous >2h with epidural / >1h without), non-reassuring fetal heart rate status, or maternal medical indications to shorten pushing (cardiac NYHA III/IV, severe cerebral vascular malformations).
  • •Absolute prerequisites: Fully dilated cervix (10 cm), ruptured membranes, vertex presentation with precise position known, engaged fetal head (minimum station >= +2 cm, low or outlet), empty maternal bladder, adequate regional or pudendal analgesia, fully informed consent, and an immediately available backup plan for emergency cesarean section.
  • •Instrument selection: Vacuum extraction (Kiwi OmniCup or soft bell) has significantly lower maternal perineal trauma (OASIS) but higher failure rates, cephalhematoma, and subgaleal hematoma risk. Forceps (Simpson, Tucker-McLane) has higher completion rates and protects the fetal head in preterm vertex, but carries higher rates of 3rd/4th-degree perineal tears and transient neonatal facial nerve palsy.
  • •Rigid stopping rules: Traction limited to contractions only; maximum 3 pulls without progressive descent; maximum 2-3 vacuum pop-offs; total traction duration under 15-20 minutes. If descent is not evident on initial traction or delivery not imminent after 3 tractions, abandon instrument and proceed to cesarean section.
DELIVERY•Grade A (High/RCTs)•SOGC Guideline No. 427 & Obstetric ERAS Society Guidelines

Cesarean Delivery: Surgical Anatomy, Indications & ERAS Postpartum Recovery

Clinical Executive Summary
  • •Classified by urgency: Category 1 (immediate threat to maternal/fetal life, e.g. cord prolapse, sustained terminal bradycardia, massive abruption, uterine rupture; decision-to-delivery target <= 30 min); Category 2 (compromise without immediate life threat, e.g. failure to progress with atypical FHR); Category 3 (early birth required, e.g. failed induction with intact membranes); Category 4 (elective scheduled, e.g. breech, repeat cesarean, placenta previa).
  • •Surgical technique: Modified Joel-Cohen or Pfannenstiel transverse skin incision, blunt digital muscle and fascial separation, lower uterine segment transverse hysterotomy (Kerr incision). Exteriorization vs in-situ uterine closure yields equivalent blood loss, but in-situ repair is associated with less nausea/vomiting during regional anesthesia. Non-closure of both visceral and parietal peritoneum significantly reduces operative time without increasing postoperative adhesion formation.
  • •Infection prophylaxis: Cefazolin 2g IV (3g if maternal weight > 120 kg) administered 15-60 minutes prior to skin incision. For unscheduled / labouring cesareans, add Azithromycin 500mg IV infusion to reduce postoperative endometritis and surgical site infections by nearly 50%. Chlorhexidine-alcohol skin preparation is superior to povidone-iodine.
  • •Obstetric ERAS protocols: Preoperative clear fluids up to 2 hours pre-op; scheduled multimodal oral analgesia (Acetaminophen 1000mg PO Q6H + Ibuprofen 600mg PO Q6H or Ketorolac IV); oral intake within 2 hours post-op; indwelling urinary catheter removal at 6-12 hours; early ambulation by 8 hours; weight-adjusted low molecular weight heparin (LMWH, Dalteparin 5000 IU SC) for high-risk VTE scores.
LABOUR•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 296 (Induction of Labour)

Induction of Labour (IOL): Foley Balloon, Dinoprostone & Oxytocin Protocols

Clinical Executive Summary
  • •Common Canadian clinical indications: Post-dates pregnancy (41+0 to 42+0 weeks), pre-labour rupture of membranes at term (PROM), hypertensive disorders of pregnancy, gestational diabetes mellitus requiring insulin, intrahepatic cholestasis of pregnancy (ICP >= 38-39w), oligohydramnios or fetal growth restriction, and maternal age >= 40 at term.
  • •Cervical assessment dictates strategy: Calculate Bishop Score first. If unfavorable (Bishop <= 6), cervical ripening is mandatory before amniotomy or oxytocin to prevent prolonged labor and failed induction cesareans.
  • •Mechanical vs Pharmacological Ripening: Mechanical intracervical Foley balloon (16-18 Fr with 30-60 mL sterile saline) yields equivalent vaginal delivery rates compared to prostaglandins with a statistically significant reduction in uterine tachysystole and fetal heart rate decelerations. Foley is safe in TOLAC/VBAC and outpatient settings. Dinoprostone 10 mg vaginal insert (Cervidil) is effective over 24h but carries higher hyperstimulation risk and is contraindicated in prior cesarean.
  • •Oxytocin titration & Tachysystole management: Low-dose protocol starts at 1-2 mU/min, titrated by 1-2 mU/min q30 minutes to achieve 3-4 contractions per 10 minutes. Tachysystole (>5 contractions in 10 minutes) requires immediate oxytocin cessation or removal of Cervidil tape, maternal lateral repositioning, IV fluid bolus, and SC terbutaline 0.25 mg if non-reassuring FHR decelerations accompany hypertonus.
EMERGENCIES•Grade A (High/RCTs)•Canadian Paediatric Society (CPS) & Neonatal Resuscitation Program (NRP) 8th Edition

Neonatal Resuscitation Program (NRP 8th Ed): The Golden Minute & Partner Perspective

Clinical Executive Summary
  • •Initial rapid evaluation (0-30 seconds): Ask 3 questions: Term gestation? Good tone (flexed)? Breathing or crying? If YES to all three: baby remains with mother for delayed cord clamping (>= 60s), drying, and direct skin-to-skin. If NO to any: clamp cord promptly and transfer immediately to pre-heated radiant warmer.
  • •The Golden Minute (First 60 seconds): Warm, dry, stimulate by gently flicking soles of feet or rubbing back, position head in 'sniffing position' (neutral alignment), and suction mouth then nose only if airway is obstructed. If apneic, gasping, or heart rate (HR) < 100 bpm: initiate Positive Pressure Ventilation (PPV) immediately using room air (21% O2 for >=35w; 21-30% O2 for <35w) at 40-60 breaths/min with PIP 20-25 cmH2O and PEEP 5 cmH2O. Attach pre-ductal pulse oximeter (right wrist) and 3-lead ECG monitor.
  • •Ventilation Corrective Steps (MR. SOPA): If HR does not rise and chest is not moving after initial PPV: (M) Mask adjustment for tight seal, (R) Reposition airway to sniffing position; reassess PPV. If still no chest rise: (S) Suction mouth and nose, (O) Open mouth and lift jaw; reassess PPV. If still no chest rise: (P) Pressure increase in 5 cmH2O increments (max 30-40 cmH2O). If still no chest rise: (A) Alternative airway (insert endotracheal tube or laryngeal mask airway).
  • •Chest Compressions & Epinephrine: If HR remains < 60 bpm despite at least 30 seconds of effective PPV via an alternative airway with 100% FiO2: begin synchronized 3:1 chest compressions (90 compressions and 30 breaths per minute; 'One-and-two-and-three-and-breathe'). If HR remains < 60 bpm after 60 seconds of coordinated compressions: administer Epinephrine via low umbilical venous catheter (UVC) 0.02 mg/kg (0.2 mL/kg of 1:10,000 solution) followed by 3 mL normal saline flush.
EMERGENCIES•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 235 (Postpartum Hemorrhage)

Postpartum Hemorrhage (PPH): The 4 T's, Uterotonic Escalation & TXA Protocols

Clinical Executive Summary
  • •PPH definition: Cumulative blood loss >= 500 mL following vaginal delivery or >= 1000 mL following cesarean delivery, or any blood loss accompanied by signs or symptoms of hypovolemia.
  • •Systematic 4 T's diagnostic evaluation: Tone (uterine atony 70%), Trauma (perineal, cervical, vaginal lacerations, uterine rupture 20%), Tissue (retained placenta or succenturiate lobe 10%), Thrombin (coagulopathy, DIC, inherited factor deficiencies 1%).
  • •Immediate pharmacological escalation algorithm: (1) Oxytocin 10-40 IU in 1000 mL crystalloid or 10 IU IM; (2) Ergometrine 0.2 mg IM (CONTRAINDICATED in hypertension/preeclampsia); (3) Carboprost (Hemabate) 250 mcg IM/intramyometrial q15min max 8 doses (CONTRAINDICATED in asthma); (4) Misoprostol 400-800 mcg sublingual/rectal.
  • •Antifibrinolytic & Tamponade: Administer Tranexamic Acid (TXA) 1g IV over 10 min immediately (within 3h of delivery) per WOMAN trial. Insert Bakri intrauterine balloon tamponade (fill with 300-500 mL sterile saline) if medical therapy fails before proceeding to laparotomy or uterine artery embolization.
EMERGENCIES•Grade A (High/RCTs)•SOGC Clinical Practice Guideline (Management of Shoulder Dystocia)

Shoulder Dystocia: The HELPERR Algorithm, Risk Factors & Neonatal Safety

Clinical Executive Summary
  • •True obstetric emergency: Delivery requiring additional obstetric maneuvers following failure of gentle downward traction on the fetal head. Recognized by the 'turtle sign' (fetal chin retracting tightly against perineum).
  • •Pathophysiology: Anterior fetal shoulder impacts behind maternal pubic symphysis (or posterior shoulder on sacral promontory). Unrelieved cord compression and fetal hypoxia develop rapidly; pH drops by ~0.04 per minute.
  • •Strict non-actions: NEVER apply fundal pressure (increases shoulder impaction and uterine rupture risk); NEVER apply excessive lateral or downward traction on the fetal head (primary mechanism of brachial plexus stretch injury / Erb's palsy).
  • •The HELPERR Protocol: (H) Help called / Start timer; (E) Evaluate for episiotomy; (L) Legs in McRoberts position (hyperflexion of maternal thighs); (P) Suprapubic pressure applied obliquely; (E) Enter internal rotational maneuvers (Rubin II / Woods corkscrew); (R) Remove posterior arm; (R) Roll patient to all-fours (Gaskin maneuver).
EMERGENCIES•Grade A (High/RCTs)•SOGC Clinical Practice Guideline (Umbilical Cord Prolapse)

Umbilical Cord Prolapse: Identification, Manual Elevation & Emergent Transfer

Clinical Executive Summary
  • •Definition: Descent of the umbilical cord through the cervix alongside (occult) or past (overt) the presenting fetal part in the presence of ruptured membranes. Incidence: 0.1-0.6%.
  • •Pathophysiology: Immediate compression of the umbilical vessels between the presenting fetal part and the bony maternal pelvis causes catastrophic fetal hypoxia, prolonged terminal bradycardia, and hypoxic-ischemic encephalopathy within minutes.
  • •Primary clinical risk factors: Artificial rupture of membranes (ARM) with unengaged head (station < 0), abnormal lie (transverse, footling breech), polyhydramnios (rapid decompression fluid wave), multiple gestation (second twin), and preterm labour.
  • •Immediate emergency action protocol: (1) Call Category 1 STAT Cesarean Section; (2) Examiner inserts hand into vagina and maintains digital manual elevation of presenting part off the cord continuously; (3) Place patient in knee-chest or steep Trendelenburg position; (4) Rapidly retrograde-fill maternal bladder with 500 mL sterile saline via Foley catheter; (5) Transfer immediately to OR.
LABOUR•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 382 (Trial of Labour After Cesarean)

Trial of Labour After Cesarean (TOLAC) & VBAC: Safety, Rupture Risks & SOGC Protocols

Clinical Executive Summary
  • •TOLAC candidates: Clinically stable individuals with one (or two) prior low transverse cesarean incisions, singleton cephalic pregnancy at term, with no contraindications to vaginal delivery.
  • •Success probability: Overall 60-80%. The single strongest predictor of VBAC success is a history of at least one prior vaginal birth (success rate rises to > 85-90%).
  • •Uterine rupture incidence: 0.47% (approx 1 in 200) in spontaneous labour with 1 prior low transverse scar; increases to 0.8-1.0% with oxytocin induction/augmentation. Rupture risk with 2 prior cesareans is ~1.5%.
  • •STRICT CONTRAINDICATIONS: Prior classical (vertical) or inverted-T incision (rupture rate 4-9%), prior extensive transmural myomectomy entering cavity, previous uterine rupture, and prostaglandin ripening agents (Dinoprostone Cervidil / Misoprostol), which multiply rupture hazard.
  • •Intrapartum surveillance: Continuous electronic fetal monitoring (EFM) is mandatory. The earliest and most consistent sign of uterine rupture is an abnormal fetal heart rate pattern (prolonged decelerations or bradycardia in 70% of ruptures), followed by loss of station, vaginal bleeding, and breakthrough pain between contractions.
LABOUR•Grade A (High/RCTs)•SOGC Clinical Practice Guideline (Management of PROM & PPROM)

Pre-Labour Rupture of Membranes (PROM & PPROM): SOGC Diagnosis & Latency Protocols

Clinical Executive Summary
  • •Classification: Term PROM (membrane rupture >= 37+0 weeks prior to contraction onset) vs Preterm PROM (PPROM, membrane rupture < 37+0 weeks; accounts for 30% of all preterm births).
  • •Diagnosis: Sterile speculum examination is mandatory. AVOID digital examinations (multiplies ascending intrauterine infection risk). Observe for clear fluid pooling in posterior fornix, nitrazine paper turning blue (pH > 6.5 vs acidic vaginal pH 4.5), microscopic ferning on dried slide, or commercial IGFBP-1 / placental alpha-microglobulin-1 (AmniSure) test.
  • •Term PROM Management: SOGC guidelines recommend active induction of labour with IV oxytocin (or oral misoprostol if cervix unfavorable), which reduces chorioamnionitis, neonatal intensive care admission, and endometritis compared to expectant management beyond 24h.
  • •PPROM Management (<37w): Latency antibiotic protocol (Ampicillin 2g IV q6h + Erythromycin/Azithromycin for 48h followed by oral Amoxicillin + Erythromycin x 5 days); single course Betamethasone (12 mg IM q24h x 2); Magnesium Sulfate for neuroprotection if < 32w; delivery recommended at 34+0 weeks or earlier if chorioamnionitis develops.
MATERNAL DISEASE•Grade A (High/RCTs)•Diabetes Canada & SOGC Clinical Practice Guidelines

Gestational Diabetes Mellitus (GDM): Screening, Glycemic Targets & Insulin Titration

Clinical Executive Summary
  • •Canadian two-step screening protocol at 24-28 weeks: 50g Glucose Challenge Test (GCT). If 1h plasma glucose < 7.8 mmol/L = normal; if 7.8 - 11.0 mmol/L = proceed to diagnostic 75g OGTT; if >= 11.1 mmol/L = gestational diabetes diagnosed immediately without OGTT.
  • •Diagnostic 75g OGTT cutoffs (Diabetes Canada): Fasting >= 5.3 mmol/L, 1-hour >= 10.6 mmol/L, 2-hour >= 9.0 mmol/L (>= 1 abnormal value confirms GDM).
  • •Target home blood glucose values: Fasting < 5.3 mmol/L, 1-hour postprandial < 7.8 mmol/L, 2-hour postprandial < 6.7 mmol/L.
  • •Pharmacotherapy: If >= 20% of readings exceed targets over 1-2 weeks despite medical nutrition therapy, initiate Insulin (first-line in Canada: NPH basal + Aspart/Lispro rapid-acting pre-meal). Metformin is second-line when insulin is infeasible or declined.
  • •Perinatal risks: Fetal macrosomia (birth weight > 4000g or > 90th percentile), shoulder dystocia, polyhydramnios, operative delivery, neonatal hypoglycemia, and childhood metabolic syndrome.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 423 (Intrahepatic Cholestasis of Pregnancy)

Intrahepatic Cholestasis of Pregnancy (ICP): Bile Acid Tiers, UDCA & Delivery Timing

Clinical Executive Summary
  • •Pathognomonic presentation: Intense, relentless pruritus predominantly affecting the palms of the hands and soles of the feet, worse at night, without a primary dermatologic rash (excoriations from scratching may be present).
  • •Diagnosis confirmed by Total Serum Bile Acids (TBA) > 10 umol/L. Transaminases (ALT, AST) are elevated in 60-80% of cases.
  • •TBA Risk Stratification (SOGC No. 423): - Mild ICP: TBA 10 - 39 umol/L. Minimal risk of adverse perinatal outcomes. - Moderate ICP: TBA 40 - 99 umol/L. Increased risk of meconium-stained fluid and preterm birth. - Severe ICP: TBA >= 100 umol/L. Highly elevated risk of sudden, unpredictable intrauterine fetal demise / stillbirth.
  • •Pharmacotherapy: Ursodeoxycholic acid (UDCA / Urso) 10-15 mg/kg/day divided BID or TID. Improves pruritus and maternal transaminases.
  • •Delivery Timing: Mild ICP (10-39): deliver at 38+0 to 39+6 weeks; Moderate ICP (40-99): deliver at 36+0 to 38+0 weeks; Severe ICP (>= 100): deliver at 35+0 to 36+0 weeks (antenatal betamethasone indicated).
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 308 (Venous Thromboembolism in Pregnancy)

Venous Thromboembolism (DVT & PE) & Anticoagulation: Diagnosis, LMWH & Delivery Timing

Clinical Executive Summary
  • •Venous Thromboembolism (VTE) is a leading direct cause of maternal mortality in Canada. Pregnancy confers a 4- to 5-fold increased VTE risk, rising to 20-fold during the first 6 weeks postpartum.
  • •Left-sided predilection: Over 80% of antepartum deep vein thromboses (DVT) occur in the left lower extremity due to compression of the left common iliac vein by the right common iliac artery and gravid uterus (May-Thurner anatomy).
  • •Diagnostic approach: D-dimer is physiologically elevated in normal pregnancy and has poor specificity; do not rule out VTE with normal non-pregnant cutoffs. Compression duplex ultrasonography of proximal veins and iliac veins is the first-line test for DVT. For suspected Pulmonary Embolism (PE), bilateral lower extremity compression Doppler is performed first; if negative, proceed to low-dose CT Pulmonary Angiogram (CT-PA) or Ventilation-Perfusion (V/Q) scan.
  • •LMWH Pharmacotherapy: Low Molecular Weight Heparin (Dalteparin or Enoxaparin) is the anticoagulant of choice. Does not cross placenta; zero teratogenicity. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban) and Warfarin are contraindicated.
  • •Critical Neuraxial Anesthesia Timing: To prevent catastrophic spinal/epidural hematoma, neuraxial anesthesia must be withheld for at least 12 hours following prophylactic LMWH, and at least 24 hours following therapeutic LMWH.
MATERNAL DISEASE•Grade A (High/RCTs)•American Thyroid Association & Endocrine Society Guidelines

Thyroid Disorders in Pregnancy: TSH Targets, Levothyroxine & Fetal Neurodevelopment

Clinical Executive Summary
  • •Fetal physiology: The fetal thyroid gland does not become functionally active until 12-14 weeks gestation. The developing fetal brain is entirely dependent on maternal transplacental passage of thyroxine (T4) during the critical first trimester.
  • •Maternal physiology: High beta-hCG cross-reacts with the TSH receptor, transiently suppressing serum TSH in the first trimester (lowest at 10-12w). Simultaneously, high estrogen increases hepatic Thyroxine-Binding Globulin (TBG) 2- to 3-fold.
  • •Canadian trimester-specific TSH upper reference limits: First trimester < 2.5 mIU/L (or lab-specific upper limit minus 0.5); Second & third trimesters < 3.0 mIU/L.
  • •Immediate Levothyroxine Adjustment: Women with pre-existing hypothyroidism must increase their Levothyroxine (Synthroid) dose by 25-30% (e.g. taking 2 extra tablets per week) immediately upon a positive home pregnancy test, followed by serum TSH check q4-6 weeks.
  • •Hyperthyroidism: Differentiate gestational transient thyrotoxicosis (hCG-mediated, resolves by 16w, no antithyroid drugs needed) from Graves' disease (TSH receptor antibodies positive). If treating Graves', use Propylthiouracil (PTU) in the first trimester (avoids methimazole embryopathy) and switch to Methimazole in the second trimester (avoids PTU hepatotoxicity).
MENTAL HEALTH•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 367 & Canadian Psychological Association

Perinatal Mental Health: PPD, Postpartum Psychosis & Paternal Depression (PPND)

Clinical Executive Summary
  • •Spectrum of Perinatal Mood & Anxiety Disorders (PMADs): 1. Postpartum Blues: Affects up to 80% of mothers. Peaks at day 3-5, characterized by emotional lability and tearfulness; self-resolves by day 10-14 without pharmacological treatment. 2. Postpartum Depression (PPD): Affects 10-15%. Screen with Edinburgh Postnatal Depression Scale (EPDS; score >= 10 indicates possible depression; score >= 13 indicates probable major depression; question 10 screens for suicidal ideation). 3. Postpartum Psychosis: 1-2 per 1000 births. Acute psychiatric emergency. Onset typically within first 2 weeks. Delusions regarding infant, hallucinations, severe confusion, insomnia. High risk of infanticide (4%) and suicide (5%). Requires immediate emergency hospitalization.
  • •Pharmacotherapy in Lactation: Sertraline is first-line SSRI of choice due to negligible breast milk excretion (< 0.5-1% infant dose) and undetectable neonatal serum levels.
  • •Paternal Postpartum Depression (PPND): Affects 8-10% of new fathers (rises to 25-50% if partner has PPD). Characterized by irritability, angry outbursts, emotional detachment, escapism (excessive work/gaming), and somatic complaints.
PRENATAL SCREENING•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 348 & CCMG Joint Policy

Prenatal Genetic Screening: NIPT, Serum Screens & Invasive Diagnostic Testing

Clinical Executive Summary
  • •Screening vs Diagnostic Distinction: Screening tests (NIPT, eFTS, SIPS, Quad) calculate statistical risk and cannot confirm chromosomal diagnosis; only diagnostic tests (Chorionic Villus Sampling CVS or Amniocentesis) provide definitive karyotype and chromosomal microarray (CMA).
  • •Non-Invasive Prenatal Testing (NIPT / cfDNA): Analyzes placental cell-free DNA in maternal plasma starting at 10 weeks. Sensitivity > 99% and false-positive rate < 0.1% for Trisomy 21 (Down syndrome). Positive Predictive Value (PPV) depends heavily on maternal age (e.g. PPV is ~50% in a 25-year-old, but > 90% in a 40-year-old).
  • •Invasive Diagnostic Risks: SOGC updated meta-analyses show modern procedure-related pregnancy loss is 0.1-0.2% (1 in 500 to 1 in 1000) for both CVS (11-14w) and Amniocentesis (15-20w), significantly lower than historical 1% figures.
  • •Manitoba Coverage: NIPT (Harmony/Panorama) is publicly insured in Manitoba for high-risk indications (maternal age >= 40 at delivery, positive serum screen, prior child with aneuploidy, or ultrasound soft marker/NT >= 3.5mm); otherwise accessible through private out-of-pocket payment (~$300-$500 CAD).
INFECTIONS•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 298 (Prevention of Early-Onset GBS Infection)

Group B Streptococcus (GBS): Screening, IV Penicillin & Neonatal Sepsis Prevention

Clinical Executive Summary
  • •Universal Screening: Rectovaginal culture swab (lower vagina, perineum, through anal sphincter into rectum without speculum) at 35+0 to 37+6 weeks gestation.
  • •Automatic Indications for Prophylaxis (No swab needed): (1) Prior infant with invasive early-onset GBS disease; (2) Documented GBS bacteriuria (> 10^4 CFU/mL) at any point during the current pregnancy (indicates heavy maternal colonization).
  • •Intrapartum Antibiotic Prophylaxis (IAP) Regimens: - First-Line: Penicillin G 5 million units IV initial dose, then 2.5 to 3.0 million units IV q4h until delivery. - Alternative (Penicillin allergy, low anaphylaxis risk): Cefazolin 2g IV initial dose, then 1g IV q8h until delivery. - High-risk anaphylaxis allergy: Clindamycin 900 mg IV q8h ONLY IF susceptibility confirmed; otherwise Vancomycin 20 mg/kg IV q8h (max 2g). - Adequate prophylaxis defined as >= 4 hours of IV antibiotic therapy prior to delivery.
  • •Impact: Routine IAP reduces early-onset neonatal GBS sepsis (pneumonia, meningitis, septic shock) by > 80%.
PRENATAL SCREENING•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 399 (Prevention of Rh Alloimmunization)

Rh Incompatibility, Alloimmunization & Anti-D Immunoglobulin (WinRho)

Clinical Executive Summary
  • •Pathophysiology: Rh-negative mother carrying an Rh-positive fetus. Fetomaternal hemorrhage introduces D-positive red cells into maternal circulation, inducing primary IgM then persistent IgG anti-D antibodies. In subsequent Rh-positive pregnancies, maternal IgG crosses the placenta causing fetal hemolysis, severe hydrops fetalis, and erythroblastosis fetalis.
  • •Screening: ABO blood typing and indirect Coombs antibody screen at initial prenatal visit and repeated at 28 weeks.
  • •Standard Canadian Prophylaxis (WinRho SDF / RhoGAM): - 300 mcg (1500 IU) IM or IV administered routinely at 28+0 weeks gestation. - 300 mcg within 72 hours of birth if newborn is confirmed Rh-positive. - Sensitizing events requiring 300 mcg: Miscarriage, elective termination, ectopic pregnancy, chorionic villus sampling, amniocentesis, external cephalic version, abdominal trauma, or antepartum hemorrhage.
  • •Fetomaternal Hemorrhage Quantification: Kleihauer-Betke acid elution test or flow cytometry to quantify fetal cells in maternal blood if massive fetomaternal hemorrhage is suspected (> 30 mL whole fetal blood); additional WinRho doses calculated accordingly.
INFECTIONS•Grade B (Moderate/Cohort)•SOGC Clinical Practice Guidelines on Viral Infections in Pregnancy

Congenital Infections: Parvovirus B19, CMV, Toxoplasmosis & Varicella

Clinical Executive Summary
  • •Parvovirus B19 (Fifth Disease / Erythema Infectiosum): Tropism for erythroid progenitor cells causing pure red cell aplasia. In pregnancy, transplacental infection can cause severe fetal anemia, high-output cardiac failure, non-immune hydrops fetalis, and fetal demise (highest risk between 13-20 weeks). Surveillance: Serial Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV) Doppler every 1-2 weeks for 8-12 weeks post-exposure; MCA-PSV > 1.5 MoM indicates severe fetal anemia requiring intrauterine umbilical cord blood transfusion.
  • •Cytomegalovirus (CMV): Most common congenital viral infection (0.5-1% of live births). Transmission via young children's saliva and urine. Causes congenital sensorineural hearing loss (leading non-genetic cause), microcephaly, periventricular calcifications, and chorioretinitis.
  • •Toxoplasma Gondii: Intracellular protozoan from cat feces or undercooked meat. Classic triad of congenital toxoplasmosis: Chorioretinitis, Hydrocephalus, Intracranial calcifications.
  • •Varicella Zoster (Chickenpox): Maternal varicella pneumonia carries high mortality. Congenital Varicella Syndrome (cicatricial skin lesions, limb hypoplasia, microphthalmia) occurs with 1st/2nd trimester infection. Administer Varicella-Zoster Immune Globulin (VarIZIG) within 96-120 hours of exposure in non-immune gravidas.
NEWBORN•Grade A (High/RCTs)•Canadian Paediatric Society (CPS) 2025 Practice Guidelines

Neonatal Hyperbilirubinemia: CPS 2025 Guidelines, Phototherapy & Kernicterus Prevention

Clinical Executive Summary
  • •Physiological vs Pathological Jaundice: Jaundice appearing in the FIRST 24 HOURS of life is ALWAYS pathological (ABO/Rh isoimmunization, erythrocyte membrane defect like spherocytosis, or sepsis). Physiological jaundice peaks at days 3-5.
  • •Universal Predischarge Screening: All infants must have Transcutaneous Bilirubin (TcB) or Total Serum Bilirubin (TSB) measured between 24-72 hours of life and plotted on the hour-specific Bhutani risk nomogram before hospital discharge.
  • •Risk factors for neurotoxicity: Gestational age < 38w, albumin < 3.0 g/dL, isoimmune hemolytic disease (positive direct Coombs / DAT), G6PD deficiency, sepsis, clinical instability.
  • •Treatment thresholds: Intensive LED phototherapy (wavelength 460-490 nm, irradiance >= 30 uW/cm2/nm). Exchange transfusion indicated for refractory hyperbilirubinemia or signs of Acute Bilirubin Encephalopathy (ABE: lethargy, retrocollis, opisthotonos, high-pitched cry) to prevent permanent kernicterus (choreoathetoid cerebral palsy, sensorineural deafness).
BREASTFEEDING•Grade A (High/RCTs)•Academy of Breastfeeding Medicine (ABM) Clinical Protocol #36

Lactation Medicine: Revised ABM Mastitis Protocol & Ankyloglossia (Tongue-Tie)

Clinical Executive Summary
  • •The Revised ABM Mastitis Spectrum Paradigm: Modern sonographic and histopathological research demonstrates that 'plugged ducts' are NOT physical milk plugs. Instead, hyperlactation and milk stasis trigger local interstitial edema and inflammatory compression of the delicate ductal system, which can progress to bacterial mastitis (Staph aureus) or breast abscess.
  • •PARADIGM SHIFT (Do NOT do): Aggressive deep tissue massage, electric toothbrushes, point-vibration, and obsessive over-pumping WORSEN tissue edema and micro-trauma. Heat before nursing increases localized vascular congestion.
  • •Modern Evidence-Based Protocol: (1) Cold compresses / ice packs between feeds to reduce inflammatory edema; (2) Scheduled NSAIDs (Ibuprofen 600mg PO TID) and Acetaminophen; (3) Physiological nursing on demand without hyper-pumping; (4) Targeted oral antibiotics (Cephalexin 500mg QID or Cloxacillin 500mg QID x 10-14 days) ONLY if systemic symptoms (fever >= 38.5°C, chills, tachycardia) persist > 24 hours.
  • •Ankyloglossia (Tongue-Tie): Short or tight lingual frenulum. Evaluate function using Hazelbaker or TABBY tool. Frenotomy is indicated ONLY for severe anatomical restriction causing persistent maternal nipple damage, shallow latch, and documented infant faltering growth despite lactation specialist consultation.
NEWBORN•Grade A (High/RCTs)•Canadian Paediatric Society Guidelines on Infant Crying & Colic

Infant Crying & Gastrointestinal Distress: PURPLE Crying, Colic vs. Reflux (GERD)

Clinical Executive Summary
  • •Normal Developmental Crying Curve (Dr. Ronald Barr): Infant crying increases at 2-3 weeks, peaks at 6-8 weeks (up to 2-3 hours/day), and resolves by 12-16 weeks. The acronym PURPLE captures normal crying: Peak of crying, Unexpected, Resists soothing, Pain-like face, Long-lasting, Evening clustering.
  • •Wessel's Criteria for Colic: Crying > 3 hours/day, > 3 days/week, for > 3 weeks in an otherwise thriving, well-fed infant with normal growth parameters.
  • •Differentiating GER from GERD: - Gastroesophageal Reflux (GER): Normal physiological retrograde flow of gastric contents through an immature lower esophageal sphincter. 'Happy spitters' with normal weight gain, happy demeanor, no breathing distress. Reassurance only; acid suppression (PPIs/H2 blockers) is INEFFECTIVE and INCREASES pediatric pneumonia and NEC risks. - GERD (Pathologic): Associated with failure to thrive, persistent food refusal, hematemesis, recurrent aspiration pneumonia, or Sandifer syndrome (paroxysmal dystonic neck extension).
  • •Cow's Milk Protein Allergy (CMPA): Non-IgE-mediated proctocolitis can present with colic and microscopic bloody/mucousy stools. A 2-week trial of maternal dairy exclusion (or extensively hydrolyzed formula) is reasonable.
FATHERHOOD•Grade B (Moderate/Cohort)•Canadian Father Involvement Initiative & Perinatal Health Guidelines

The Father's First 40 Days: Postpartum Tactical Operations, Sleep Shifts & Boundary Bouncing

Clinical Executive Summary
  • •Physiological Maternal Vulnerability in the 4th Trimester: Massive endocrine withdrawal (estrogen and progesterone plunge to menopausal levels within 48h postpartum), uterine involution (from 1000g to 60g over 6 weeks), continuous tissue remodeling of pelvic floor and abdominal fascia, and intense metabolic energy expenditure (exclusive lactation requires +500 kcal/day and 3L fluids/day).
  • •Sleep Fragmentation Architecture: Normal newborn sleep architecture consists of 50-60 minute ultradian cycles with rapid arousals. Maternal sleep deprivation (< 4 hours continuous sleep) severely impairs prefrontal cortex executive function and multiplies PPD odds 3-fold.
  • •The Paternal Buffer Effect: Active paternal logistical co-parenting (shielding mother from external social stress, coordinating meals, managing infant soothing) directly correlates with lower maternal cortisol and higher rates of successful exclusive breastfeeding at 6 months.
RELATIONSHIP•Grade B (Moderate/Cohort)•SOGC & Pelvic Health Solutions Clinical Consensus

Postpartum Intimacy & Relationship Architecture: The 6-Week Myth & Pelvic Floor Recovery

Clinical Executive Summary
  • •The '6-Week Green Light' Myth: The 6-week obstetric checkup verifies cervical os closure and perineal incision epithelialization. It is NOT a physiological or psychological mandate for intercourse. In cohort studies, over 80% of postpartum women experience dyspareunia (painful intercourse) at 3 months, and over 40% at 6 months.
  • •Lactational Hypoestrogenism: Prolactin suppresses gonadotropin-releasing hormone (GnRH) and ovarian estradiol synthesis. The resulting hypoestrogenic vaginal state causes marked mucosal thinning, loss of elasticity, and reduced natural lubrication identical to severe postmenopausal atrophic vaginitis. Water- or silicone-based lubricants are essential.
  • •Pelvic Floor Biomechanics: Whether delivery was vaginal or cesarean (9 months of carrying 12-15 kg anterior load stresses the levator ani), pelvic floor dysfunction (stress urinary incontinence, pelvic organ prolapse, hypertonic pelvic floor) affects > 30% of primiparas. Pelvic floor physical therapy (PFPT) is strongly recommended at 6-8 weeks postpartum.
  • •Contraception Timing: Ovulation can occur prior to the first menses, even in lactating individuals. Estrogen-containing pills (combined OCPs) decrease milk supply; progesterone-only pills (Micronor), progestin implants (Nexplanon), or levonorgestrel IUDs (Mirena) are preferred.
EMERGENCIES•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 383

Placenta Previa, Placenta Accreta Spectrum (PAS) & Vasa Previa

Clinical Executive Summary
  • •Placenta previa: internal cervical os covered by placenta; low-lying placenta: placental edge within 20mm of internal os on transvaginal ultrasound (TVS).
  • •Placenta Accreta Spectrum (PAS): abnormal trophoblastic invasion into myometrium (accreta, increta, percreta); risk surges exponentially with number of prior cesarean deliveries and anterior previa.
  • •Vasa previa: fetal vessels traversing membranes over internal os unsupported by placenta or umbilical cord; rupture of membranes carries >50% fetal exsanguination mortality.
  • •Strict pelvic rest; scheduled cesarean delivery at 36+0 to 37+6 weeks for stable previa, 34+0 to 35+6 for PAS in specialized tertiary centre (HSC Women's) with multidisciplinary surgical team and cell salvage.
EMERGENCIES•Grade B (Moderate/Cohort)•SOGC Clinical Practice Guidelines

Placental Abruption (Abruptio Placentae)

Clinical Executive Summary
  • •Premature separation of normally situated placenta prior to delivery; affects ~0.5–1.0% of pregnancies.
  • •Classic clinical triad: Sudden, continuous abdominal/back pain, uterine tenderness with hypertonic ('woody') baseline tone, and vaginal bleeding (concealed behind retroplacental clot in ~20% of cases).
  • •Major complications: Consumptive coagulopathy / Disseminated Intravascular Coagulation (DIC), hypovolemic hemorrhagic shock, renal failure, acute fetal hypoxia, stillbirth.
  • •Immediate emergency resuscitation: 2 large-bore (16G) IVs, blood bank STAT type and crossmatch (4 units PRBCs), continuous EFM, emergency cesarean for maternal or fetal distress.
EMERGENCIES•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 382

Uterine Rupture vs. Occult Scar Dehiscence

Clinical Executive Summary
  • •Uterine rupture is full-thickness disruption of all uterine wall layers including visceral peritoneum, resulting in fetal extrusion or acute maternal hemorrhage; incidence ~0.5–0.7% in TOLAC with single low-transverse scar.
  • •Scar dehiscence: occult separation of myometrial scar with intact visceral peritoneum; clinically asymptomatic and discovered incidentally at repeat cesarean.
  • •Cardinal sign of rupture: Sudden, prolonged fetal bradycardia (>70% of cases). Other signs: cessation of uterine contractions, loss of fetal station, severe sharp breakthrough scar pain, maternal hypotension.
  • •Management: Immediate crash cesarean section under general anesthesia; neonatal resuscitation team at bedside; surgical uterine repair vs emergent peripartum hysterectomy.
EMERGENCIES•Grade B (Moderate/Cohort)•SOGC Clinical Practice Guidelines

Amniotic Fluid Embolism (AFE) / Anaphylactoid Syndrome of Pregnancy

Clinical Executive Summary
  • •Rare (1 in 40,000 to 50,000 births) catastrophic non-IgE immune-mediated cardiopulmonary collapse caused by fetal antigens entering maternal venous circulation.
  • •Classic clinical tetrad: Acute hypoxia / respiratory failure, sudden cardiogenic shock, profound consumptive coagulopathy (DIC) with massive hemorrhage, and seizures / altered mental status.
  • •Management: High-quality CPR, Left Uterine Displacement (LUD), immediate perimortem cesarean section if maternal arrest > 4 minutes (relieves aortocaval compression and improves maternal ROSC).
  • •Evidence-based pharmacotherapy: The A-OK Protocol (Atropine 1mg, Ondansetron 8mg, Ketorolac 30mg IV) to counteract pulmonary vasospasm and thromboembolism cascade.
DELIVERY•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 400

Breech Presentation & External Cephalic Version (ECV)

Clinical Executive Summary
  • •Breech presentation occurs in ~25% of pregnancies at 28 weeks, but spontaneous cephalic version reduces this to ~3-4% at term (37+ weeks).
  • •Types: Frank breech (hips flexed, knees extended; most common ~65%), Complete breech (hips and knees flexed ~25%), Incomplete / Footling breech (one or both feet down; high risk of cord prolapse).
  • •External Cephalic Version (ECV): Transabdominal manipulation to turn fetus from breech to cephalic; offered at 36-37 weeks. Overall success rate ~50% in nulliparas, ~65% in multiparas.
  • •Tocolysis (subcutaneous terbutaline or sublingual nitroglycerin) and neuraxial analgesia significantly increase ECV success rates. Delivery mode: Planned cesarean is standard in Canada following the Term Breech Trial, unless strict SOGC criteria for vaginal breech are met by experienced clinicians.
DELIVERY•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 396

Intrapartum Fetal Surveillance & Electronic Fetal Monitoring (EFM)

Clinical Executive Summary
  • •SOGC No. 396 Canadian standard: Intermittent Auscultation (IA) with Doppler is recommended for healthy low-risk term pregnancies in active labour.
  • •Continuous Electronic Fetal Monitoring (EFM) indicated for: IOL with oxytocin, epidural analgesia, meconium, vaginal bleeding, maternal fever, prior cesarean (TOLAC), or atypical IA.
  • •FHR Parameters: Baseline (110–160 bpm), Variability (Moderate 6–25 bpm indicates normal cerebral oxygenation), Accelerations, Decelerations (Early: benign head compression; Late: uteroplacental insufficiency; Variable: cord compression).
  • •Canadian Tri-Classification: Normal (Category 1), Atypical (Category 2), Abnormal (Category 3). Intrauterine resuscitation: maternal lateral repositioning, IV fluid bolus, stopping oxytocin, scalp stimulation.
DELIVERY•Grade A (High/RCTs)•SOGC & Canadian Anesthesiologists' Society (CAS)

Labour Analgesia & Anesthesia: Epidural, Spinal, CSE & Nitrous Oxide

Clinical Executive Summary
  • •Lumbar epidural analgesia is the most effective modality for intrapartum pain relief (Cochrane Grade A).
  • •Contemporary 'low-dose' mobile epidural regimens (e.g., Bupivacaine 0.0625–0.1% or Ropivacaine + Fentanyl 2 mcg/mL via Patient-Controlled Epidural Analgesia [PCEA] with background infusion) minimize motor block and preserve pushing ability.
  • •Epidural hypotension (sympathectomy-induced decrease in systemic vascular resistance) occurs in ~10–15%; treated with IV crystalloid preloading/co-loading and titrated IV Phenylephrine (50–100 mcg) or Ephedrine.
  • •Post-Dural Puncture Headache (PDPH) occurs in ~1% of epidural placements ('wet tap'); postural fronto-occipital throbbing headache relieved when supine. Epidural blood patch (EBP) provides >90% definitive resolution.
DELIVERY•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 303 & 373

Perineal Trauma, Episiotomy & 3rd/4th Degree Sphincter Tears (OASI)

Clinical Executive Summary
  • •Perineal tears occur in >85% of primiparous vaginal births; the vast majority are 1st or 2nd degree.
  • •Obstetric Anal Sphincter Injuries (OASI) comprise 3rd and 4th degree tears (incidence ~3–5% in primiparas): 3a (<50% external anal sphincter [EAS]), 3b (>50% EAS), 3c (both EAS and internal anal sphincter [IAS] torn), 4th degree (sphincter complex plus anal epithelium/rectal mucosa disrupted).
  • •Risk factors: Operative vaginal delivery (forceps > vacuum), nulliparity, fetal macrosomia (>4000g), persistent occiput posterior (OP) position, midline episiotomy.
  • •OASI Management: Systematic rectal exam to diagnose; repair in operating room under adequate regional anesthesia by experienced provider; single-dose prophylactic IV Cefazolin + Metronidazole; stool softeners (PEG 3350) for 2–4 weeks; pelvic floor physiotherapy referral at 6 weeks.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 426

Chronic Hypertension & Superimposed Preeclampsia in Pregnancy

Clinical Executive Summary
  • •Chronic hypertension: SBP >= 140 or DBP >= 90 mmHg diagnosed prior to pregnancy or before 20 weeks gestation.
  • •The landmark CHAP Trial (NEJM 2022) established that tight BP control (< 140/90 mmHg) significantly reduces preeclampsia with severe features, medically indicated preterm delivery, and abruption without impairing fetal growth.
  • •Universal prophylactic Low-Dose Aspirin (ASA 162 mg PO at bedtime) initiated before 16 weeks gestation reduces superimposed preeclampsia by up to 50-60%.
  • •First-line oral antihypertensive agents in Canada: Labetalol, Nifedipine XL, and Methyldopa. ACE inhibitors, ARBs, and direct renin inhibitors are strictly contraindicated due to fetopathy and neonatal renal failure.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC & Canadian Cardiovascular Society (CCS)

Cardiac Disease in Pregnancy & CARPREG II Risk Stratification

Clinical Executive Summary
  • •Normal maternal cardiovascular adaptations: 40–50% plasma volume expansion, 30–50% cardiac output increase, 25% heart rate increase, marked decrease in systemic vascular resistance (nadir at 24 weeks).
  • •Benign physiological flow murmurs (systolic ejection murmurs <= Grade 2/6 along left sternal border) are heard in >90% of pregnant individuals. Diastolic murmurs, pansystolic murmurs, or murmurs with thrill are ALWAYS pathological.
  • •CARPREG II Risk Score (Sillman et al., JACC 2018): 10 weighted clinical predictors quantify maternal cardiac event risk: prior cardiac event (3 pts), baseline NYHA class III/IV (2 pts), high-risk mechanical valve or systemic ventricular dysfunction (2 pts), etc. (Score 0-1: ~5% risk; >=4: >40% risk).
  • •Peripartum Cardiomyopathy (PPCM): Unexplained dilated cardiomyopathy developing in late pregnancy or first 5 months postpartum with LVEF < 45%. Prompt echocardiography indicated for progressive orthopnea or dyspnea.
MATERNAL DISEASE•Grade A (High/RCTs)•Canadian Thoracic Society (CTS) & SOGC

Asthma Exacerbations & Respiratory Management in Pregnancy

Clinical Executive Summary
  • •Asthma affects 8-10% of pregnant women; the 'Rule of Thirds' applies: 1/3 improve, 1/3 remain unchanged, 1/3 worsen (peak exacerbation vulnerability at 24-36 weeks).
  • •Fetal oxygenation depends entirely on maternal arterial oxygen saturation; maternal SpO2 must be maintained >= 95% to preserve fetal umbilical venous pO2.
  • •Inhaled Corticosteroids (Budesonide preferred) and Short-Acting Beta-Agonists (Salbutamol) are safe and essential throughout all trimesters; poorly controlled maternal asthma carries far higher fetal risk (preterm birth, SGA, preeclampsia) than any asthma medication.
  • •Acute severe asthma exacerbation: High-flow oxygen, nebulized Salbutamol + Ipratropium bromide, and early systemic corticosteroids (Prednisone 50 mg PO daily x 5 days); systemic steroids do not increase major congenital malformation risk.
MATERNAL DISEASE•Grade A (High/RCTs)•Canadian Association of Gastroenterology (CAG) & SOGC

Inflammatory Bowel Disease (Crohn's & Ulcerative Colitis) in Pregnancy

Clinical Executive Summary
  • •Preconception disease control is paramount: conception during active IBD flare triples risks of spontaneous preterm birth, low birth weight, and fetal loss.
  • •Safety of IBD medications: 5-ASAs (Mesalamine), Thiopurines (Azathioprine / 6-MP), and Anti-TNF Biologics (Infliximab, Adalimumab) have proven maternal-fetal safety profiles; stopping effective maintenance medications carries catastrophic flare risk.
  • •Transplacental antibody transfer: Anti-TNF IgG1 monoclonal antibodies actively cross placenta via FcRn receptors primarily in third trimester (>30 weeks). Infant should defer live-attenuated vaccines (Rotavirus, BCG) for 6–12 months postpartum if third-trimester biologic exposure occurred.
  • •Mode of Delivery: Vaginal delivery is safe and recommended for most IBD patients. Cesarean delivery is strictly indicated for ACTIVE perianal disease (active fistulae or abscesses) or prior ileal pouch-anal anastomosis (IPAA / J-pouch) to protect fecal continence.
MATERNAL DISEASE•Grade A (High/RCTs)•Canadian League Against Epilepsy (CLAE) & SOGC

Epilepsy & Antiseizure Medications (ASMs) in Pregnancy

Clinical Executive Summary
  • •Over 90% of women with well-controlled epilepsy have healthy pregnancies and uncomplicated births.
  • •Preconception High-Dose Folic Acid: 5 mg daily PO recommended to mitigate teratogenic neural tube defect risk.
  • •Teratogenic Risk Stratification: Sodium Valproate carries highest teratogenicity (>10% major congenital malformations, neural tube defects, and 30-40% risk of childhood neurocognitive impairment / ASD); avoid in women of childbearing potential. Lamotrigine (Lamictal) and Levetiracetam (Keppra) are preferred first-line agents with lowest malformation rates (~2-3%, comparable to general population baseline).
  • •Pharmacokinetic Alterations: Estrogen-induced hepatic UGT1A4 glucuronidation increases Lamotrigine clearance by up to 200–300%, causing precipitous drops in serum concentrations; monthly therapeutic drug monitoring (TDM) and proactive dose titration required.
  • •Labour Protocol: Ensure continuation of oral ASMs during active labour; status epilepticus in labour treated with IV Lorazepam 4 mg.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guidelines

Renal Disease, Asymptomatic Bacteriuria & Acute Pyelonephritis

Clinical Executive Summary
  • •Physiological changes: GFR and renal blood flow increase by 50%, resulting in lower normal serum creatinine (normal pregnancy Cr is 35–65 µmol/L; a value > 75–80 µmol/L indicates renal impairment). Progesterone causes ureteral smooth muscle dilation and physiological hydronephrosis (Right > Left due to dextrorotated uterus).
  • •Asymptomatic Bacteriuria (ASB): Screen at first prenatal visit with midstream urine culture; treat all positive cultures (>=10^8 CFU/L). Untreated ASB progresses to acute pyelonephritis in 20–40% of pregnancies.
  • •Acute Pyelonephritis: Leading non-obstetric cause of maternal septic shock and ARDS in pregnancy; causes release of inflammatory cytokines triggering preterm labour. Hospital admission for IV Cefazolin or Ceftriaxone mandatory.
  • •Antibiotic safety: Nitrofurantoin and Cefalexin safe in 1st/2nd trimesters. Avoid Nitrofurantoin at term (37+ weeks) due to theoretical neonatal hemolytic anemia in G6PD deficiency; avoid Trimethoprim-Sulfamethoxazole in 1st trimester (folate antagonist) and at term (neonatal kernicterus).
DELIVERY•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 386

Preterm Labour, Tocolysis & Antenatal Neuroprotection

Clinical Executive Summary
  • •Spontaneous preterm labour: regular uterine contractions accompanied by progressive cervical dilation between 24+0 and 36+6 weeks.
  • •Triage assessment: Transvaginal ultrasound cervical length (CL < 25 mm before 34 weeks indicates elevated risk; >30 mm has >95% negative predictive value) and Fetal Fibronectin (fFN).
  • •The Three Evidence-Based Antenatal Interventions: 1. Antenatal Corticosteroids (Betamethasone 12 mg IM q24h x 2 doses between 24+0 and 34+6w) reduces neonatal death, RDS, and IVH by ~50%. 2. Magnesium Sulfate for Neuroprotection (4g IV load over 20 min then 1g/h infusion) if delivery expected < 34 weeks reduces cerebral palsy and gross motor dysfunction by ~30%. 3. Tocolysis (Oral Nifedipine 20 mg PO stat then 10–20 mg q4–6h) for 48 hours to allow completion of steroid course and transfer to tertiary NICU (HSC Winnipeg).
PRENATAL SCREENING•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 388

Anatomy Ultrasound (18–22w) & Demystifying Ultrasound Soft Markers

Clinical Executive Summary
  • •Detailed 18–22 week anatomy scan: Systematic survey of intracranial structures, face/palate, 4-chamber heart & outflow tracts, spine, abdominal wall, kidneys, bladder, and four extremities.
  • •Demystifying 'Soft Markers': Normal anatomical variants with slightly higher prevalence in aneuploidy, but in ISOLATION have negligible clinical significance in the era of normal first-trimester screening or NIPT.
  • •Echogenic Intracardiac Focus (EIF): Microcalcification of papillary muscle; found in ~5% of normal fetuses (benign normal variant; no follow-up needed if NIPT negative).
  • •Choroid Plexus Cysts (CPC): Small transient fluid cysts in brain ventricles (~1-2% of normal fetuses); resolve spontaneously by 26-28 weeks without neurodevelopmental effect.
  • •Single Umbilical Artery (SUA): 2-vessel cord (1 artery, 1 vein); present in ~1% of singletons; isolated finding requires third-trimester fetal growth scan at 28–32w.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guidelines

Amniotic Fluid Disorders: Oligohydramnios & Polyhydramnios

Clinical Executive Summary
  • •Amniotic fluid volume reflects dynamic equilibrium between fetal swallowing/resorption and fetal micturition/pulmonary fluid secretion.
  • •Sonographic definition: Deepest Vertical Pocket (DVP) is preferred over Amniotic Fluid Index (AFI) to avoid overdiagnosing oligohydramnios. Oligohydramnios: DVP < 2 cm (or AFI < 5 cm). Polyhydramnios: DVP >= 8 cm (or AFI >= 24 cm).
  • •Oligohydramnios differential: Ruptured membranes (PPROM), uteroplacental insufficiency / fetal growth restriction, fetal renal agenesis / urinary tract obstruction (Potter sequence), maternal ACEi/NSAID use.
  • •Polyhydramnios differential: Maternal gestational/pregestational diabetes (fetal osmotic diuresis), fetal swallowing obstruction (duodenal/esophageal atresia, micrognathia), neuromuscular disorders, multiple gestation (TTTS), idiopathic (50%).
DELIVERY•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 391

Multiple Gestation: Dichorionic vs. Monochorionic Twin Management

Clinical Executive Summary
  • •Chorionicity determination by first-trimester ultrasound (11-14 weeks) is the single most crucial prognostic step: Dichorionic-Diamniotic (DCDA) exhibits the 'lambda' or 'twin-peak' sign; Monochorionic-Diamniotic (MCDA) exhibits the 'T-sign'.
  • •MCDA twins share a single placenta with vascular anastomoses (arterio-venous, arterio-arterial, veno-venous), carrying unique risks: Twin-to-Twin Transfusion Syndrome (TTTS, ~10-15%), Twin Anemia Polycythemia Sequence (TAPS, ~5%), and selective Fetal Growth Restriction (sFGR).
  • •Ultrasound surveillance frequency: DCDA: Growth scan every 4 weeks from 20w. MCDA: Ultrasound every 2 weeks from 16w to delivery for DVP, bladder visualization, and umbilical/MCA Dopplers.
  • •Delivery timing: DCDA: 37+0 to 37+6 weeks. MCDA: 36+0 to 36+6 weeks. Monochorionic-Monoamniotic (MCMA): 32+0 to 34+0 weeks by cesarean due to cord entanglement.
MATERNAL DISEASE•Grade A (High/RCTs)•SOGC Clinical Practice Guideline No. 440

Fetal Growth Restriction (FGR/IUGR) & Umbilical Doppler Surveillance

Clinical Executive Summary
  • •Small for Gestational Age (SGA): Estimated Fetal Weight (EFW) < 10th percentile for gestational age (includes constitutionally small, healthy fetuses).
  • •Fetal Growth Restriction (FGR): Pathological failure of fetus to achieve genetic growth potential due to placental insufficiency; defined as EFW < 3rd percentile OR EFW < 10th percentile WITH abnormal Doppler indices (umbilical artery, uterine artery, or MCA).
  • •Umbilical Artery Doppler Cascading Deterioration: Normal positive forward diastolic flow -> Decreased diastolic flow -> Absent End-Diastolic Flow (AEDF) -> Reversed End-Diastolic Flow (REDF) reflecting severe placental vascular obliteration (>70%).
  • •Delivery Timing: Isolated SGA with normal Dopplers: deliver at 38+0 to 39+6w. Umbilical artery AEDF: deliver at 33+0 to 34+0w (with antenatal steroids). Umbilical artery REDF: deliver at 30+0 to 32+0w (or immediately if abnormal venous Dopplers / ductus venosus reversal).
NEWBORN•Grade A (High/RCTs)•Canadian Paediatric Society (CPS 2024 Practice Statement)

Neonatal Sepsis & Early-Onset Infection (EOS): CPS Guidelines

Clinical Executive Summary
  • •Early-Onset Sepsis (EOS): Systemic bacterial infection within first 72 hours of life; leading causative pathogens in Canada are Group B Streptococcus (GBS ~40-50%) and Escherichia coli (~30-40%, predominant in preterm infants).
  • •Maternal Risk Factors: Inadequate intrapartum GBS antibiotic prophylaxis (<4h before delivery), chorioamnionitis / intra-amniotic infection (fever >= 38.0°C + maternal/fetal tachycardia or uterine tenderness), PROM >= 18 hours, preterm delivery < 37 weeks.
  • •Clinical Presentation: Subtly non-specific: Temperature instability (HYPOTHERMIA < 36.5°C is more common than fever in neonates!), respiratory distress (tachypnea > 60, grunting, retractions), poor perfusion (cap refill > 3s), lethargy, weak suck, hypoglycemia.
  • •Diagnostic Workup & Empiric Therapy: Blood culture (minimum 1.0 mL), CBC, lumbar puncture if clinically unstable; empiric IV Ampicillin (50 mg/kg q12h) + IV Gentamicin (4–5 mg/kg q24–36h) initiated immediately.
NEWBORN•Grade A (High/RCTs)•Canadian Paediatric Society (CPS)

Transient Tachypnea of the Newborn (TTN) vs. Respiratory Distress Syndrome (RDS)

Clinical Executive Summary
  • •Transient Tachypnea of the Newborn (TTN, 'wet lung'): Delayed clearance and resorption of fetal alveolar fluid via epithelial sodium channels (ENaC); most common in elective cesarean deliveries without labour and late-preterm/near-term infants.
  • •Respiratory Distress Syndrome (RDS): Primary alveolar surfactant deficiency causing high surface tension, microatelectasis, and ventilation-perfusion mismatch; incidence inversely proportional to gestational age (affects ~60% at <28w, ~5% at 34w).
  • •Chest Radiography: • TTN: Prominent perihilar vascular markings ('sunburst' appearance), fluid in horizontal interlobar fissure, hyperinflation, flattening of diaphragms. • RDS: Diffuse reticulogranular 'ground-glass' appearance with prominent air bronchograms and low lung volumes.
  • •Management: Nasal Continuous Positive Airway Pressure (CPAP 5–7 cm H2O) provides positive end-expiratory pressure to keep alveoli open and push fluid into lymphatic channels. TTN typically resolves spontaneously within 24–72 hours.
NEWBORN•Grade A (High/RCTs)•Canadian Paediatric Society (CPS)

Infant Sleep Architecture, Wake Windows & Circadian Development

Clinical Executive Summary
  • •Neonatal sleep physiology: Total sleep duration 14–17 hours per 24 hours distributed across multiple 2–4 hour bouts; absence of circadian rhythm until 8–12 weeks of life when endogenous melatonin and cortisol cycles synchronize to light/dark zeitgebers.
  • •Ultradian Sleep Cycle: Infant sleep cycle duration is 50–60 minutes (vs 90–100 min in adults); ~50% is Active (REM) sleep characterized by rapid irregular breathing, facial twitches, vocal grunts, and eye movements (essential for synaptic plasticity and brain growth). Parents frequently mistake Active Sleep for waking up and intervene prematurely.
  • •Developmental Wake Windows: 0–4 weeks: 45–60 min; 4–12 weeks: 60–90 min; 3–6 months: 1.5–2.5 hours. Exceeding wake windows triggers hypothalamic-pituitary-adrenal (HPA) axis cortisol release, hyperarousal, and difficulty settling.
  • •The 4-Month 'Sleep Regression': Physiological shift as primitive infant sleep architecture transitions permanently into mature adult-like 4-stage non-REM/REM cycling with brief micro-arousals between sleep cycles.
NEWBORN•Grade A (High/RCTs)•Cadham Provincial Laboratory & CPS

Manitoba Newborn Metabolic Screening & Benign Neonatal Rashes

Clinical Executive Summary
  • •Manitoba Newborn Screening Program: Universal bloodspot screening (Guthrie heel-prick card) collected between 24 and 48 hours of life, processed centralized at Cadham Provincial Laboratory (750 William Ave, Winnipeg).
  • •Screening Panel: Tests for 40+ treatable conditions across 5 categories: Amino acid disorders (PKU), Organic acid disorders, Fatty acid oxidation (MCAD), Endocrine (Congenital Hypothyroidism, CAH), Hemoglobinopathies (Sickle Cell), Cystic Fibrosis, Spinal Muscular Atrophy (SMA), and Severe Combined Immunodeficiency (SCID via TREC assay).
  • •Benign Cutaneous Manifestations in Newborns: • Erythema Toxicum Neonatorum (ETN): Erythematous macules with central yellow-white papules/pustules; smear shows eosinophils; benign self-limiting within 7–14 days. • Milia: 1–2 mm pearly white epidermal inclusion cysts on nose and chin; resolve spontaneously without popping. • Neonatal Cephalic Pustulosis (Baby Acne): Inflammatory response to Malassezia yeast at 2–4 weeks; self-resolving. • Nevus Simplex ('Stork Bite' / 'Angel Kiss'): Capillary vascular malformation on nape of neck or eyelids; fade over 1–2 years.
NEWBORN•Grade A (High/RCTs)•Canadian Paediatric Society (CPS) & Health Canada

Starting Solids & Early Allergen Introduction: CPS Guidelines

Clinical Executive Summary
  • •Exclusive breastfeeding or formula feeding recommended for first 6 months of life; complementary solid foods introduced around 6 months when developmental milestones are met.
  • •Developmental Readiness Signs: Good head/neck control, ability to sit with minimal support, loss of tongue extrusion (thrust) reflex, intentional reaching and opening mouth for food.
  • •First Foods Must Be Iron-Rich: Full-term infant iron stores accumulated in utero deplete by 6 months of age; prioritize meat, poultry, fish, cooked eggs, legumes, tofu, and iron-fortified cereals twice daily to support neurocognitive development.
  • •Early & Proactive Allergen Introduction (LEAP & EAT Trials / CPS 2021): High-risk infants (severe eczema or existing egg allergy) should be introduced to common allergenic foods (peanut, cooked egg) starting at ~4–6 months once developmentally ready. Delaying allergen introduction beyond 6 months significantly increases food allergy risk.
FATHERHOOD•Grade A (High/RCTs)•Canadian Mental Health Association & CPS

Paternal Postnatal Depression (PPND) & Mental Health in Fathers

Clinical Executive Summary
  • •Paternal Postnatal Depression (PPND) affects 8–10% of new fathers in the first postpartum year (surging to 25–50% if the mother is concurrently depressed).
  • •Atypical Male Depression Presentation: Men are less likely to report sadness or crying; PPND frequently manifests as irritability, explosive anger/rage, emotional numbing, compulsive working, escapism (excessive video gaming, gambling, screen addiction), alcohol/substance use, and somatic complaints (headaches, dyspepsia).
  • •Neuroendocrine Changes in Fathers: Biological fathers undergo significant hormonal remodeling around birth: testosterone drops by ~30% (facilitating nurturance), while oxytocin, prolactin, and cortisol rise. Maladaptive cortisol dysregulation correlates with paternal depression.
  • •Screening & Intervention: Edinburgh Postnatal Depression Scale (EPDS) is validated in fathers (using a lower threshold score >= 9-10 maximizes sensitivity). Psychotherapy (CBT), peer father support groups, and SSRI pharmacotherapy (sertraline/escitalopram) are effective.
FATHERHOOD•Grade A (High/RCTs)•Service Canada & Manitoba Employment Standards

Canadian Parental Leave (EI) & Manitoba Employment Standards for Fathers

Clinical Executive Summary
  • •Federal Employment Insurance (EI) Parental Benefits Framework: • Maternity Benefits: 15 weeks maximum @ 55% average weekly insurable earnings (birthing parent only). • Parental Benefits (Shared between parents): - Standard Option: 40 weeks shared (maximum 35 weeks for one parent) @ 55% insurable earnings (up to statutory weekly cap). - Extended Option: 69 weeks shared (maximum 61 weeks for one parent) @ 33% insurable earnings. • The 'Use It or Lose It' Parental Sharing Benefit: Provides 5 additional weeks (standard) or 8 additional weeks (extended) exclusively for the second parent (father/partner); cannot be transferred to the mother. • Manitoba Employment Standards Code: Provides job-protected, unpaid parental leave of up to 63 continuous weeks for employees with >= 7 months service with the same employer; employee must be reinstated to same or comparable job with identical pay and benefits.